These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26149787)

  • 1. Understanding pharmaceutical polymorphic transformations II: crystallization variables and influence on dosage forms.
    Sood J; Sapra B; Bhandari S; Tiwary AK
    Ther Deliv; 2015; 6(6):721-40. PubMed ID: 26149787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of water in the physical stability of solid dosage formulations.
    Airaksinen S; Karjalainen M; Shevchenko A; Westermarck S; Leppänen E; Rantanen J; Yliruusi J
    J Pharm Sci; 2005 Oct; 94(10):2147-65. PubMed ID: 16136577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of Polymers as Pharmaceutical Excipients in Solid Oral Dosage Forms.
    Debotton N; Dahan A
    Med Res Rev; 2017 Jan; 37(1):52-97. PubMed ID: 27502146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of crystal habit on the dissolution behaviour of simvastatin crystals and its relationship to crystallization solvent properties.
    Bukovec P; Benkic P; Smrkolj M; Vrecer F
    Pharmazie; 2016 May; 71(5):263-8. PubMed ID: 27348970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular, Solid-State and Surface Structures of the Conformational Polymorphic Forms of Ritonavir in Relation to their Physicochemical Properties.
    Wang C; Rosbottom I; Turner TD; Laing S; Maloney AGP; Sheikh AY; Docherty R; Yin Q; Roberts KJ
    Pharm Res; 2021 Jun; 38(6):971-990. PubMed ID: 34009625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding pharmaceutical polymorphic transformations I: influence of process variables and storage conditions.
    Sood J; Sapra B; Bhandari S; Jindal M; Tiwary AK
    Ther Deliv; 2014 Oct; 5(10):1123-42. PubMed ID: 25418270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design.
    Vandecruys R; Peeters J; Verreck G; Brewster ME
    Int J Pharm; 2007 Sep; 342(1-2):168-75. PubMed ID: 17573214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manipulation of Pharmaceutical Polymorphic Transformation Process Using Excipients.
    Tian B; Ding Z; Zong S; Yang J; Wang N; Wang T; Huang X; Hao H
    Curr Pharm Des; 2020; 26(21):2553-2563. PubMed ID: 32053064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disparities of Single-Particle Growth Rates in Buried Versus Exposed Ritonavir Crystals within Amorphous Solid Dispersions.
    Griffin SR; Takanti N; Sarkar S; Song Z; Vogt AD; Danzer GD; Simpson GJ
    Mol Pharm; 2020 Dec; 17(12):4564-4571. PubMed ID: 33151697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of temperature and moisture on the amorphous-to-crystalline transformation of stavudine.
    Strydom S; Liebenberg W; Yu L; de Villiers M
    Int J Pharm; 2009 Sep; 379(1):72-81. PubMed ID: 19540323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spherical crystallization of drugs.
    Kovačič B; Vrečer F; Planinšek O
    Acta Pharm; 2012 Mar; 62(1):1-14. PubMed ID: 22472445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisolvent crystallization of pharmaceutical excipients from aqueous solutions and the use of preferred orientation in phase identification by powder X-ray diffraction.
    Crisp JL; Dann SE; Blatchford CG
    Eur J Pharm Sci; 2011 Apr; 42(5):568-77. PubMed ID: 21382490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The polymorphism of progesterone: stabilization of a 'disappearing' polymorph by co-crystallization.
    Lancaster RW; Karamertzanis PG; Hulme AT; Tocher DA; Lewis TC; Price SL
    J Pharm Sci; 2007 Dec; 96(12):3419-31. PubMed ID: 17621678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supercritical carbon dioxide processing of active pharmaceutical ingredients for polymorphic control and for complex formation.
    Moribe K; Tozuka Y; Yamamoto K
    Adv Drug Deliv Rev; 2008 Feb; 60(3):328-38. PubMed ID: 18006109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical co-crystals-an opportunity for drug product enhancement.
    Miroshnyk I; Mirza S; Sandler N
    Expert Opin Drug Deliv; 2009 Apr; 6(4):333-41. PubMed ID: 19348603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formation of bicalutamide nanodispersion for dissolution rate enhancement.
    Li C; Li C; Le Y; Chen JF
    Int J Pharm; 2011 Feb; 404(1-2):257-63. PubMed ID: 21093558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal growth formation in melt extrudates.
    Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
    Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow method.
    Solymosi T; Angi R; Basa-Dénes O; Ránky S; Ötvös Z; Glavinas H; Filipcsei G; Heltovics G
    Eur J Pharm Biopharm; 2015 Aug; 94():135-40. PubMed ID: 26003815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extension of the dissolution-precipitation model for kinetic elucidation of solvent-mediated polymorphic transformations.
    Jakubiak P; Schuler F; Alvarez-Sánchez R
    Eur J Pharm Biopharm; 2016 Dec; 109():43-48. PubMed ID: 27648958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.